Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Empagliflozin and Vildagliptin in Type 2 Diabetes
NCT05359432Phase 4Completed
- Sponsor
- Getz Pharma
- Start
- Jul 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin, vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Getz Pharma. Started Jul 2020; status: completed.
02
Drugs
empagliflozinvildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05359432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359432.